- Home
- SWIM vs ARVN Comparison
SWIM vs ARVN Comparison
Compare SWIM & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- ARVN
- Stock Information
- Founded
- SWIM 1956
- ARVN 2015
- Country
- SWIM United States
- ARVN United States
- Employees
- SWIM N/A
- ARVN N/A
- Industry
- SWIM Plastic Products
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- SWIM Industrials
- ARVN Health Care
- Exchange
- SWIM Nasdaq
- ARVN Nasdaq
- Market Cap
- SWIM 844.9M
- ARVN 676.2M
- IPO Year
- SWIM 2021
- ARVN 2018
- Fundamental
- Price
- SWIM $7.31
- ARVN $9.54
- Analyst Decision
- SWIM Hold
- ARVN Buy
- Analyst Count
- SWIM 3
- ARVN 23
- Target Price
- SWIM $6.93
- ARVN $17.80
- AVG Volume (30 Days)
- SWIM 480.2K
- ARVN 2.5M
- Earning Date
- SWIM 11-04-2025
- ARVN 11-05-2025
- Dividend Yield
- SWIM N/A
- ARVN N/A
- EPS Growth
- SWIM N/A
- ARVN N/A
- EPS
- SWIM N/A
- ARVN N/A
- Revenue
- SWIM $521,828,000.00
- ARVN $372,800,000.00
- Revenue This Year
- SWIM $9.17
- ARVN N/A
- Revenue Next Year
- SWIM $5.38
- ARVN N/A
- P/E Ratio
- SWIM N/A
- ARVN N/A
- Revenue Growth
- SWIM N/A
- ARVN 299.57
- 52 Week Low
- SWIM $4.56
- ARVN $5.90
- 52 Week High
- SWIM $8.46
- ARVN $28.83
- Technical
- Relative Strength Index (RSI)
- SWIM 42.04
- ARVN 53.98
- Support Level
- SWIM $7.03
- ARVN $9.01
- Resistance Level
- SWIM $8.11
- ARVN $10.18
- Average True Range (ATR)
- SWIM 0.27
- ARVN 0.43
- MACD
- SWIM -0.04
- ARVN -0.05
- Stochastic Oscillator
- SWIM 17.21
- ARVN 41.41
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.